---
title: "Bispecific ADCs: Can 1 + 1 Be Greater Than 2?"
description: How bispecific antibody-drug conjugates aim to improve ADC selectivity, internalization, and resistance, and the design challenges early clinical data reveal.
image: https://www.crystalbiosolutions.com/hubfs/AI-Generated%20Media/Images/ADC%20Research%20Lab%20Analysis%20with%20Scientist%20and%20Advanced%20Equipment.png
---

![Crystal Bio Solutions logo](https://www.crystalbiosolutions.com/hs-fs/hubfs/Crystal%20Bio%20Solutions%20logo.webp?width=330&height=150&name=Crystal%20Bio%20Solutions%20logo.webp)

- Bioanalysis & Biomarkers 
    - [All Bioanalysis & Biomarker Services](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [PK Assays for Biologics & ADCs](https://www.crystalbiosolutions.com/services/pk-bioanalysis)
    - [NAb & ADA Immunogenicity Assays](https://www.crystalbiosolutions.com/ada-and-nab-testing-in-biologics-pk-efficacy-and-regulatory-risk)
    - [Receptor Occupancy Assays](https://www.crystalbiosolutions.com/services/receptor-occupancy-assays)
- Biologics CMC Analytical 
    - [All Biologics CMC Analytical Services](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Developability Assessment](https://www.crystalbiosolutions.com/services/biologics-developability-assessment)
    - [Extended Characterization by HRMS](https://www.crystalbiosolutions.com/services/biologics-extended-characterization-hrms)
    - [Biotransformation & In Vivo CQA](https://www.crystalbiosolutions.com/services/biotransformation-in-vivo-cqa)
- [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
- Solutions 
    - [ADC Programs](https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc)
    - [Regulatory Affairs Support](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)

- [Resources](https://www.crystalbiosolutions.com/news-and-events)
- [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
- [About Us](https://www.crystalbiosolutions.com/about-us)
- [Locations](https://www.crystalbiosolutions.com/locations)
- [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Request a Proposal](https://www.crystalbiosolutions.com/contact-us)

Nov 22, 2026

# Bispecific ADCs: Can 1 + 1 Be Greater Than 2?

How bispecific antibody-drug conjugates aim to improve ADC selectivity, internalization, and resistance, and the design challenges early clinical data reveal.

![Bispecific ADCs: Can 1 + 1 Be Greater Than 2?](https://www.crystalbiosolutions.com/hubfs/AI-Generated%20Media/Images/ADC%20Research%20Lab%20Analysis%20with%20Scientist%20and%20Advanced%20Equipment.png)\\

Over the past decade, antibody-drug conjugates (ADCs) have matured as treatments for hematologic and solid tumors and have achieved striking clinical success. Even after several generations of innovation, wider use has exposed persistent problems, especially toxicity and resistance. These include limited efficacy against a single target because of tumor heterogeneity; resistance from target downregulation, mutation, or bypass activation; and toxicity from insufficient target specificity.

Bispecific ADCs are an emerging answer. They use the specificity of a bispecific antibody to target tumor cells more precisely, and cross-linking can promote co-internalization of two targets, raising the efficiency of payload delivery into tumor cells. Bispecific antibodies are usually classified by mechanism as cell-bridging or non-bridging (antigen cross-linking), and by structure as IgG-like (with Fc) or non-IgG-like (without Fc). Not every bispecific format suits an ADC. The right format is the one that improves selectivity, internalization, payload delivery, or resistance.

## Selectivity

The ideal ADC target is highly expressed only in diseased tissue, but very few such antigens exist. Normal tissues usually express the target too, which causes on-target, off-tumor toxicity. A bispecific design can help an ADC distinguish diseased from normal tissue and lower toxicity. Target selection is the precondition for success. Because a bispecific ADC binds two antigens, the downstream effects of the antigen pair must be considered carefully, including internalization, recycling, turnover, lysosomal degradation, and intrinsic biology.

## Internalization and lysosomal trafficking

Beyond tumor selectivity, an ADC must be internalized and trafficked to lysosomes to work, especially when it uses a non-cleavable linker. HER2 is internalized and highly expressed in many tumors, which makes it an attractive ADC target. However, HER2 recycles rapidly and traffics poorly to lysosomes, which may explain the disappointing results of ado-trastuzumab emtansine (T-DM1) in several trials. Bispecific strategies can address this in two ways:

1. **Pair the tumor target with a rapidly internalizing receptor.** One arm binds an existing fast-internalizing receptor that promotes lysosomal trafficking and ADC degradation, while the other arm binds the tumor cell surface target. This widens the choice of target antigens beyond those that internalize well without rapid recycling.
2. **Target two epitopes on the same antigen.** A biparatopic antibody binds two different epitopes of one antigen. This increases tumor selectivity and also induces receptor clustering and cross-linking, which enhances internalization and lysosomal trafficking.

## Early clinical experience

By May 2024, 10 bispecific ADCs had entered clinical trials, and the number has grown since. Early results suggested that safety and efficacy had not yet matched theoretical expectations. Designing a bispecific ADC is not a simple "1 + 1"; it requires joint optimization of the bispecific antibody, conjugation chemistry and site, and payload.

## Challenges for bispecific ADCs

1. **Limited targets.** Most programs focus on HER2, c-MET, and EGFR, although bispecific strategies could extend to targets that internalize poorly or are expressed at low levels.
2. **Heterogeneous conjugation.** Random chemical conjugation of payloads through functional groups risks a heterogeneous product.
3. **Target interplay.** The relative parameters of the two targets, and how they interact, are hard to balance.
4. **New safety questions.** A new technology brings potential safety issues that are not yet well understood.

## What this means for bioanalysis

Bispecific ADCs add complexity to every analytical question an ADC already raises: drug-to-antibody ratio (DAR) and its change in vivo, conjugated and unconjugated payload, total antibody, and immunogenicity against more domains. See our [ADC program support](https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc), or [contact us](https://www.crystalbiosolutions.com/contact-us) to discuss your molecule.

## References

1. Maruani A. Bispecifics and antibody-drug conjugates: a positive synergy. Drug Discov Today Technol. 2018;30:55–61. doi:10.1016/j.ddtec.2018.09.003.
2. Bispecific antibody drug conjugates: making 1+1\>2. Acta Pharmaceutica Sinica B. Published online January 20, 2024.

![Crystal Bio Solutions logo (footer)](https://www.crystalbiosolutions.com/hubfs/Logo_CBS-%E7%AB%96%E7%89%88-%E5%8F%8D%E7%99%BD.png)

- [Our Services](https://www.crystalbiosolutions.com) 
    - [Bioanalysis & Biomarkers](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [Biologics CMC Analytical](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
    - [Regulatory Affairs](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)
- [Information](https://www.crystalbiosolutions.com/news-and-events) 
    - [About Us](https://www.crystalbiosolutions.com/about-us)
    - [Quality & Compliance](https://www.crystalbiosolutions.com/quality-and-compliance)
    - [News & Events](https://www.crystalbiosolutions.com/news-and-events)
    - [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
    - [Scientific Articles](https://www.crystalbiosolutions.com/news-and-events/tag/blog)
    - [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Contact](https://www.crystalbiosolutions.com/contact-us) 
    - [Email Us](mailto:cbs_bd@crystalpharmatech.com)
    - [Contact Form](https://www.crystalbiosolutions.com/contact-us)
    - [Our Locations](https://www.crystalbiosolutions.com/locations)
    - [Crystal Group](https://www.crystalbiosolutions.com/about-us#crystal-group) 
          - [Crystal Pharmatech](https://www.crystalpharmatech.com/)
          - [Crystal NAX](https://www.crystalnax.com/)

<https://www.linkedin.com/company/crystal-bio-solutions/> [Follow us on LinkedIn News, events and openings](https://www.linkedin.com/company/crystal-bio-solutions/)

- [Privacy Policy](https://www.crystalbiosolutions.com/policies/privacy-policy)
- [Terms of Service](https://www.crystalbiosolutions.com/policies/terms-of-service)

Copyright © 2026 Crystal Bio Solutions, Inc. All rights reserved.

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "CBS Marketing Team",
    "url" : "https://www.crystalbiosolutions.com/news-and-events/author/cbs-marketing-team"
  },
  "dateModified" : "2026-11-22T17:58:50.699Z",
  "datePublished" : "2026-11-22T17:58:50.000Z",
  "headline" : "Bispecific ADCs: Can 1 + 1 Be Greater Than 2?",
  "image" : [ "https://www.crystalbiosolutions.com/hubfs/AI-Generated%20Media/Images/ADC%20Research%20Lab%20Analysis%20with%20Scientist%20and%20Advanced%20Equipment.png" ],
  "mainEntityOfPage" : {
    "@id" : "https://www.crystalbiosolutions.com/news-and-events/bispecific-adcs-can-1-1-be-greater-than-2",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://www.crystalbiosolutions.com/hubfs/Crystal%20Bio%20Solutions%20logo.webp"
    },
    "name" : "Crystal Bio Solutions"
  }
}
```